Answers are grounded in this paper and cite their sources.
Receptor activator of nuclear factor-κB ligand (RANKL) is indispensable for osteoclast differentiation, activation, and bone resorption. While the relative contributions of membrane-bound RANKL (mRANKL) and soluble RANKL were historically debated, evidence from the past decade increasingly establishes mRANKL as the primary driver of osteoclastogenesis. However, a systematic literature synthesis integrating these diverse cellular sources and structural modalities remains lacking. It has also not been systematically defined which cellular sources of RANKL - arising from bone marrow mesenchymal lineage cells or hematopoietic lineage cells - play dominant roles in driving osteoclast activation. Clarifying these distinct forms and sources of RANKL will refine the conceptual framework of osteoclast regulation and provide a mechanistic basis for next-generation antiresorptive therapies that selectively target specific RANKL modalities to achieve more durable skeletal protection.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: